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Genetically modified animals continue to provide important insights
into the molecular basis of health and disease. Research has focused
mostly on genetically modified mice, although other species like pigs
resemble the human physiology more closely. In addition, cross-
species comparisons with phylogenetically distant species such as
chickens provide powerful insights into fundamental biological and
biomedical processes. One of the most versatile genetic methods
applicable across species is CRISPR-Cas9. Here, we report the gener-
ation of transgenic chickens and pigs that constitutively express Cas9
in all organs. These animals are healthy and fertile. Functionality of
Cas9 was confirmed in both species for a number of different target
genes, for a variety of cell types and in vivo by targeted gene dis-
ruption in lymphocytes and the developing brain, and by precise
excision of a 12.7-kb DNA fragment in the heart. The Cas9 transgenic
animals will provide a powerful resource for in vivo genome editing
for both agricultural and translational biomedical research, and will
facilitate reverse genetics as well as cross-species comparisons.
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CRISPR-Cas9
Chickens and pigs are the most important livestock speciesworldwide. They are not only important sources of food, but
also valuable models for evolutionary biology and biomedical sci-
ence. Pigs share a high anatomical and physiological similarity with
humans and are an important species for translational biomedical
research, for example, in the areas of cancer, diabetes, neurode-
generative, and cardiovascular diseases (1–3). They also resemble
the human pathophenotype more closely than rodents. For ex-
ample, pig models for familial adenomatous polyposis (FAP) de-
velop polyps in the large intestine as observed in human patients
(4), whereas mouse FAP models develop them in the small intes-
tine (5). In contrast to mammals, chickens are phylogenetically
distant vertebrates from humans, but they were instrumental in the
field of developmental biology due to the easy access to the em-
bryonated egg. They are used for studying neurological and car-
diovascular functions (6–8) and provided key findings in B cell
development and graft versus host responses (9–11). Genetically
modified livestock species also hold great promise for agriculture by
offering new approaches for disease control, such as genome-edited
pigs resistant to Porcine Reproductive and Respiratory Syndrome
or Avian Leucosis Virus (ALV)-resistant chickens (12–15).
Due to the lack of fully functional embryonic stem cells, genetic
engineering in pigs and chickens has been a laborious, inefficient,
and time-consuming procedure (16). The generation of pigs with
precise germline modifications required gene targeting in somatic
cells followed by somatic cell nuclear transfer. This also is not
practical in chickens, where precise alteration of the genome only
became possible with recent improvements in the cultivation and
manipulation of germline-competent primordial germ cells (PGCs)
(17–19). These modified PGCs can be injected into the blood vessel
system of stage 13 to 15 (Hamburger−Hamilton [HH]) embryos to
produce germline chimeras and, by further breeding, genetically
modified chickens.
With the advent of synthetic endonucleases such as CRISPR-
Cas9 efficiency of targeted germline modification has improved
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in both species (20–23). It still requires the generation and breeding
of new founder lines, which is time consuming in large animals. To
circumvent the need for generating germline-modified animals, at-
tempts have been made to carry out genome editing directly in
specific organs or tissues (24–27). But this has been hampered by
the need to deliver both Cas9 and the required guide RNA (gRNA)
and by the limited cargo capacity of viral vectors. To bypass this
drawback, Cas9 transgenic mice have been generated, requiring
delivery of only the respective gRNAs (28).
Here, we describe the generation of both Cas9 transgenic pigs
and chickens that ubiquitously express Cas9 endonuclease and
provide proof of its function in vitro and in vivo. These animals
provide an innovative and efficient model for in vivo genome
editing to assess gene function in health and disease.
Results
Generation of Cas9 Transgenic Animals. Cas9 transgenic pigs were
generated by targeted placement of Streptococcus pyogenes Cas9
(SpCas9) at the ROSA26 locus (Fig. 1A), which was previously
shown to support abundant ubiquitous transgene expression in
pigs (29, 30). Five percent of G418-resistant cell clones showed
correct gene targeting, expressed SpCas9, and were used for so-
matic cell nuclear transfer resulting in two liveborn piglets (#41
and #42) (Fig. 1C). For both animals, correct gene targeting was
confirmed by long-range PCR across the 5′ and 3′ junctions of the
targeted allele and DNA sequence analysis (SI Appendix, Fig. S1).
Monoallelic insertion of SpCas9 was shown by PCR across the
nontargeted ROSA26 wild-type allele (SI Appendix, Fig. S1).
Sanger sequencing of the PCR product confirmed sequence in-
tegrity of the ROSA26 wild-type allele. Pig #42 served as a
founder animal of an SpCas9 transgenic herd.
Cas9 transgenic chickens were generated by phiC31 integrase-
mediated integration of an SpCas9 expression construct (Fig. 1B)
into a chicken endogenous pseudo attP site, which has previously
been reported to increase the integration frequency in PGCs (31).
These PGCs already carried an enhanced green fluorescent protein
(EGFP) transgene, and Cas9-EGFP-PGC clones were screened for
SpCas9 expression by immunofluorescence and flow cytometry (SI
Appendix, Fig. S2A). Functionality was tested by transient trans-
fection with an expression vector carrying a gRNA directed against
the EGFP gene. Analysis by flow cytometry showed that 17% of
SpCas9-expressing cells lost EGFP fluorescence, while no reduc-
tion was observed for the MOCK control (SI Appendix, Fig. S2B).
From 60 injections with modified PGCs (PGC clone 4) into stage
13 to 15 HH embryos, 19 male germline chimeras were obtained.
Upon sexual maturity, four chimeras were mated with wild-type
hens to obtain fully transgenic SpCas9 chickens (Fig. 1D). As
expected, EGFP and Cas9 segregated independently in the
offspring.
The transgene copy number was determined in both species
via droplet digital PCR (ddPCR) and revealed a single copy of
SpCas9 in pigs and chickens (SI Appendix, Fig. S3 A and B). Both
Cas9 transgenic chickens and pigs developed normally, showed
no obvious abnormalities (i.e., in weight gain; SI Appendix, Fig.
S3C), and were fertile.
Ubiquitous Expression of SpCas9 in Transgenic Animals. SpCas9 mes-
senger RNA (mRNA) expression was analyzed in different tissues
from chickens (proventriculus, spleen, duodenum, cecal tonsil, ce-
cum, liver, kidney, lung, pancreas, heart, brain, thymus, muscle, and
gonads) and pigs (stomach, spleen, small intestine, aorta, liver,
kidney, lung, and heart). Analysis of the housekeeping genes glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) for pig samples
and β-actin for chicken samples served to validate the quality of
RNA. The RT-PCR showed SpCas9 expression in all samples of
both species (Fig. 1 E and F).
Functionality of SpCas9. To examine the functionality of SpCas9
in vitro, we isolated different primary cell types from Cas9-
expressing animals and transfected those with gRNAs directed
against EGFP, β2-microglobulin (B2M), a component necessary
for the assembly of the MHC class I complex, or against the C-X-
C chemokine receptor type 4 (CXCR4) for the avian experiments.
Targets in porcine cells were the endogenous B2M gene and the
α-1,3-galactosyltransferase (GGTA1) gene responsible for the
presentation of alpha-gal epitopes on the cell surface of most
mammals, which play a crucial role in hyperacute rejection in
pig-to-primate xenotransplantation (21, 32). Successful inactiva-
tion of these target genes can be assessed by flow cytometry.
Cas9 transgenic pigs. Porcine ear fibroblasts (PEFs) were isolated
from the founder pigs (#41 and #42), and transiently transfected
with a vector containing a gRNA against B2M (β2m-gRNA).
Flow cytometry analyses revealed that 28.1% of cells from
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Fig. 1. Generation and expression analyses of SpCas9 transgenic pigs and chickens. (A) Structure of the ROSA26-SpCas9 targeting vector and targeting
strategy to introduce SpCas9 gene into the porcine ROSA26 locus. Exons are indicated by numbered boxes, and regions of homology are indicated by dotted
lines. (B) Expression vector used for the generation of SpCas9-expressing PGCs. (C) SpCas9 transgenic founder pigs. (D) SpCas9 transgenic rooster and hen. (E)
RT-PCR analyses of SpCas9 transgenic pig organs. SpCas9 expression is shown by a 415-bp PCR product, and porcine GAPDH (576 bp) serves as a control. (F) RT-
PCR analyses of SpCas9 transgenic chicken organs. SpCas9 expression in all tissues analyzed is shown by a 265-bp PCR product, and β-actin (300 bp) serves as
a control.
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animal #41 and 20.6% of cells from pig #42 lost expression of
β2m (Fig. 2A). To test whether chemically modified synthetic
gRNAs can increase the editing efficiencies, as previously shown
for human cells (33), PEFs were transfected with a chemically
modified synthetic gRNA directed against B2M. In flow cytometry
analyses, 58.5% of PEF cells were negative for β2m expression
(Fig. 2B). To confirm functionality in different cell types, an
SpCas9 transgenic offspring was killed, and porcine adipose-
derived mesenchymal stem cells (PADMSCs), porcine aorta en-
dothelial cells (PAECs), and porcine kidney fibroblasts (PKFs)
were isolated, transiently transfected with a vector containing a
gRNA against B2M, and analyzed by flow cytometry. Homozygous
inactivation of the target gene was observed in all cell types
(63.1% of cells in PADMSCs, 35.8% in PAECs, and 16.2% in
PKFs), confirming the functionality of SpCas9 (Fig. 2C). The
different efficiencies reflect the difference in transfectability of the
various cell types.
To assess SpCas9 transgene function in a more complex tissue,
organoids were generated from the colonic mucosa of an SpCas9-
expressing pig (SI Appendix, Fig. S4A) and transiently transfected
with a vector carrying a gRNA directed against GGTA1. Tracking
of Indels by Decomposition (TIDE) analysis of the sequenced
PCR fragment across the gRNA target site revealed a total target
cleavage efficiency of 12.0% in the organoids (SI Appendix,
Fig. S4B).
Cas9 transgenic chicken. Primary chicken embryonic fibroblasts
(CEFs) were derived from an EGFP/Cas9 transgenic embryo. A
gRNA against EGFP was delivered by the retroviral RCASBP(A)
(Replication-Competent ALV LTR with a Splice acceptor) vector,
which is a derivative of the avian Rous sarcoma virus (34, 35).
Six days posttransduction, 69.3% of cells were negative for EGFP
expression as measured by flow cytometry (Fig. 2D). In compari-
son, transfection of CEFs with a synthetic unmodified gRNA
against EGFP was less efficient, with 27.0% loss of EGFP ex-
pression after 48 h (Fig. 2E). Next, genome editing was demon-
strated in primary CD45+ peripheral blood mononuclear cells
derived from the spleen of a Cas9-expressing chicken. Cells were
electroporated with two 2′-O-methyl phosphorothioate linkage-
modified synthetic gRNAs directed against CXCR4 or B2M,
resulting in a significant reduction of CXCR4 (P < 0.05; 31% of
cells) or β2m expression (P < 0.01; 22.1% of cells), as demon-
strated in three independent replicates (Fig. 2F and SI Appendix,
Fig. S5).
In Vivo Genome Editing. The results above showed efficient gene
inactivation in various primary cell types isolated from both
SpCas9-expressing pigs and chickens. To confirm that genome
editing would work equally well in vivo, gRNAs were directly
delivered to SpCas9 transgenic animals.
Cas9 transgenic pig. While, in the previous in vitro experiments,
only individual gRNAs were used to achieve gene inactivation,
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Fig. 2. SpCas9 functionality in primary cells derived from SpCas9 transgenic pigs and chickens. (A) PEFs derived from ear tissue of SpCas9 founder pigs #41
and #42 transfected with a construct carrying a gRNA against B2M or GGTA1 (MOCK-transfected control). (B) PEFs derived from an SpCas9 transgenic pig and
transfected with chemically modified gRNA against porcine B2M or P16 (MOCK-transfected control). (C) PADMSCs, PKFs, and PAECs derived from an SpCas9
transgenic piglet and transfected with a construct carrying a gRNA against B2M or GGTA1 (MOCK-transfected control). (D) CEFs derived from an SpCas9-
expressing chicken and transfected with RCASBP(A)-EGFP-gRNA or RCASBP(A)-INF-gRNA (MOCK-transfected control). (E) CEFs transfected with a synthetic
gRNA against EGFP or B2M (MOCK-transfected control). (F) Splenic CD45+ PMBCs derived from an SpCas9-expressing chicken and transfected with chemically
modified gRNA against B2M or CXCR4. Shown is one representative example of three independent replicates.
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the goal of the in vivo experiment was to assess whether a precise
excision of a large DNA fragment (12.7 kb) could be achieved in
heart tissue by delivering two gRNAs using an adeno-associated
viral (AAV) vector. The target gene was MYBPC3, which encodes
the cardiac myosin-binding protein C (cMyBP‐C). Mutations in
MYBPC3 cause neonatal cardiomyopathy (36). To deliver gRNAs
directly into the heart, polyamidoamine (PAMAM)-coated AAV2/9
vectors encoding two gRNAs targeting MYBPC3 exons 6 and 23
and an mCherry expression construct were injected into the coro-
nary target artery (left anterior descending artery, LAD) of Cas9-
expressing pigs at an age of 3.5 mo. After 3 wk, the experiment was
terminated, and heart tissue sections from the distal LAD perfusion
area were analyzed by fluorescence microscopy imaging. DNA was
isolated from tissue sections with the highest number of mCherry-
positive cells (Fig. 3A). PCR analysis and subsequent sequencing
revealed precise CRISPR-Cas9−mediated deletion of the 12.7-kb
DNA fragment between the two gRNA target sites located in exons
6 and 23 of the porcine MYBPC3 gene (g.4175_16906del)
(Fig. 3 B–D). Indel mutations at the individual gRNA target sites
alone were not observed. Quantitative PCR showed 8% efficiency
for the deletion of the 12.7-kb fragment (SI Appendix, Fig. S6).
Cas9 transgenic chicken. To examine the efficiency of in ovo ge-
nome editing, two different methods were tested. First, 3-d-old
embryonated eggs were injected in the allantoic cavity with a DF-
1 cell line producing the infectious RCASBP(A) vector encoding
the B2M gRNA. The β2m expression on bursa-derived B cells
was then analyzed by flow cytometry and showed a significant
reduction of β2m on the cell surface compared to MOCK-
transduced controls (Fig. 3E). The percentage of cells lacking
β2m expression varied between the individual embryos, ranging
from 30 to 80%, most likely reflecting different transduction effi-
ciencies. Amplicon sequencing confirmed editing at the gRNA
target site (SI Appendix, Fig. S9). As an alternative approach,
tissue-specific in ovo electroporation was tested. Brain tissues from
chicken embryos were electroporated with vectors containing ei-
ther a gRNA against B2M or EGFP. In the latter case, fluores-
cence microscopy imaging clearly showed a loss of EGFP in Cas9/
EGFP-positive embryos (Fig. 3 F–K). In contrast, no EGFP loss
was observed in Cas9/EGFP embryos electroporated with a gRNA
against B2M. TIDE analysis for EGFP targeting revealed a total
cleavage efficiency of 11.5% (embryo #5) and 6.8% (embryo #7)
(SI Appendix, Fig. S7) and, for B2M, 13.8% (embryo #6), 11.8%
(embryo #12), and 11.1% (embryo #22) (SI Appendix, Fig. S8).
Discussion
Besides describing the establishment of a pig line that ubiqui-
tously expresses SpCas9, we also reported the generation of
SpCas9 transgenic chickens. Proof of principle studies showed
the functionality of the SpCas9 transgene in vivo and in vitro
by employing different methods for gRNA delivery, such as
A
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Fig. 3. In vivo genome editing in SpCas9 transgenic pigs and chickens. (A) Porcine heart section of an SpCas9-transgenic pig transduced with an AAV virus
encoding gRNAs directed against the porcine MYBPC3 gene and an mCherry reporter construct. The mCherry signal (red) is marked with white arrows.
Sections were counterstained with DAPI (blue) and WGA-Alexa488 conjugate (green). (B) Structure of the porcine MYBPC3 locus. Exons are indicated by
numbered boxes. Primers are shown as black arrows, and gRNA target sites are shown as black flashes. Simultaneous CRISPR-Cas9−mediated cleavage at the
gRNA target sites in exons 6 and 23 leads to the excision of a 12.7-kb fragment. (C) Detection of the 1.2-kb PCR product resulting from successful CRISPR-
Cas9−mediated excision of the 12.7-kb fragment. As PCR conditions were optimized for the detection of the 1.2-kb fragment, the much larger 13.9-kb wild-
type fragment was not amplified. (D) Sequencing result across the junction site upon CRISPR-Cas9−mediated excision of the 12.7-kb fragment between both
gRNA target sites. (E) In ovo genome editing of B2M by RCASBP(A)-mediated gRNA delivery. At ED3, embryonated eggs were injected with RCASBP(A)-β2m-
gRNA−infected DF-1 cells or RCASBP(A)-EGFP-gRNA−infected DF-1 cells (MOCK control). At ED18, bursal B cells were analyzed for β2m expression by flow
cytometry (n ≥ 4). *P < 0.05. Statistical analysis was done by Student´s t test, and error bars represent the SD. (F−K) In vivo genome editing via in ovo
electroporation in chickens. At ED2, midbrain vesicles of EGFP-positive embryos were electroporated with pBlueScript II SK (+) vector containing a gRNA
against EGFP or β2m, and embryos were collected at ED 12. DAPI-treated midbrain sections were analyzed for EGFP expression, by fluorescence microscopy.
(F) Horizontal section of midbrain OT of MOCK β2m-gRNA−transfected embryo with clear EGFP signal in every cell (neurons, glia, and blood vessels). (G and H)
Frontal sections of OT of EGFP-gRNA−transfected embryos showing a prominent reduction of EGFP fluorescence. (I–K) Magnified sections from F−H illus-
trating tectal layering and loss of EGFP in J and K. Blood vessels (BV) and optical input fibers (OF) still expressing EGFP marked with white arrows.
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transfection with synthetic gRNAs, in ovo electroporation, or
viral-based delivery methods. While all approaches resulted in
editing of the target locus, the efficiency depended on the gRNA
delivery method, ranging from 8% in vivo to 70% homozygous
gene inactivation in vitro. Optimization of gRNA delivery clearly
has to be a main objective for in vivo genome editing. Besides im-
proving viral-based methods, such as AAVs or lentiviral transduc-
tion, nonviral delivery approaches should be investigated, such as
delivery via polymer-based carriers or lipid nanoparticles (37–39).
The Cas9 transgenic chickens were generated by phiC31-
mediated transgene integration into an endogenous pseudo attP
site (40). Animals carrying a single copy of SpCas9 were healthy
and fertile. However, if cell clones with more than a single copy of
SpCas9 were used to produce Cas9 transgenic birds, embryo le-
thality between embryonic day 18 (ED18) and ED21 was ob-
served. This is in contrast with SpCas9 homozygous mice and pigs,
where two transgene copies are tolerated. As integration occurred
randomly in the chicken, this could be a result of insertional
mutagenesis or, more likely, due to the potential toxic effect of
high Cas9 expression as observed for Cre-recombinase expressing
mice (41).
For the pig, the SpCas9 transgene was inserted in the ROSA26
locus. This locus is known to be a “safe harbor” for transgene ex-
pression without interrupting the function of essential endogenous
genes (42). Moreover, previous reports showed that it is readily
targeted, supports abundant ubiquitous expression, and is dis-
pensable for normal physiology and development (29, 30). Unlike
previous work, where a Cre-inducible Cas9-expressing line has
been generated (43), our pig line expresses a single copy of SpCas9
ubiquitously under the control of the CBh promoter. This elimi-
nates the need for two consecutive recombination events to occur
and should increase editing efficiency. Ubiquitously Cas9-
expressing pigs are healthy and fertile and could be bred to ho-
mozygosity, consistent with findings in ROSA26-Cas9−expressing
mice (28).
The functionality of the SpCas9 transgene was tested not only in
a series of porcine primary cells but also in porcine colonic
organoids, which form a more complex three-dimensional struc-
ture. Our group has an interest in modeling human cancers in pigs,
such as colorectal cancer (4). Modification of colonic organoids
from SpCas9-expressing pigs enables in vitro local inactivation of
single or multiple tumor-relevant genes and the analysis of on-
cogenic transformation prior to subsequent autologous reimplan-
tation, as shown for mice (44). This procedure as well as the
option to inactivate multiple tumor-suppressor genes directly
in vivo will eliminate the need to generate germline-modified pigs
and will allow closer simulation of human oncogenesis.
In vivo genome editing in Cas9-expressing pigs and chickens
was confirmed using three different approaches. Previous studies
reported successful in vivo genome editing in avian species by
direct injection of adenoviral delivered CRISPR-Cas9 compo-
nents into the blastoderm of a newly laid egg (45), but the need
to deliver the Cas9 endonuclease has generally been the limiting
factor, due to its large size. Here, a retroviral RCAS vector
expressing only the gRNA to efficiently inactivate B2M in avian
B cells was used. In addition, tissue-specific in vivo genome
editing without the need for viral vectors was demonstrated in
chicken embryos via in ovo-electroporation of brain tissue. For
the targeted delivery of two gRNAs to the porcine heart, an
AAV vector was used, resulting in the precise excision of a 12.7-
kb DNA fragment. Overall, there are very few reports on direct
in vivo genome editing in pigs. We previously used AAV vectors
carrying an intein-split Cas9 system and a pair of gRNAs to
mediate genome editing in muscles (46), while Wang et al. (43)
used a lentiviral-mediated approach to deliver gRNAs into lungs
of inducible Cas9-expressing pigs. Even though both approaches
are successful, one required the transduction of cells with two
viruses simultaneously, whereas the other required the delivery
not only of the gRNA but also of Cre-recombinase to first activate
the latent Cas9 gene, potentially reducing efficiency and risking
Cre-toxicity in the target cells. In contrast to these reports, our
model requires the delivery of only gRNAs and is not dependent
on cotransduction of multiple viruses or Cas9 activation.
In conclusion, we generated a versatile tool and showed effi-
cient genome editing of five different target genes in a number of
cell types and in vivo, confirming SpCas9 functionality in both pig
and chicken. We are confident that the SpCas9 transgenic pigs and
chickens provide a powerful platform for in vitro and in vivo ge-
nome editing in mammalian and nonmammalian livestock species,
eliminating the need for Cas9 delivery in vivo and in vitro.
Methods
Generation of SpCas9 and gRNA Constructs. For the generation of SpCas9
expression constructs, we used the sequence of a human codon-optimized
SpCas9 obtained from pX330-U6-Chimeric_BB-CBh-SpCas9 from Feng Zhang
(Addgene plasmid # 42230; http://n2t.net/addgene:42230; RRID:Addgene_
42230). Oligonucleotides were synthesized by Eurofins Genomics.
For stable integration in chickenPGCs, the SpCas9 construct contained an attB
site to ensure the insertion of the transgene using phiC31 integrase (40). SpCas9
was amplified by PCR, and the PCR product was assembled with a −8.7-kb
backbone construct using NEBuilder HiFi DNA Assembly Cloning Kit (New
England Biolabs) according to manufacturer’s instructions. The SpCas9 expres-
sion cassette contained a 1.3-kb chicken β-actin promoter, followed by an SV40
nuclear localization signal (NLS), a 4.1-kb SpCas9 gene, a nucleoplasmin NLS,
and an SV40 poly(A). The generated construct contained a CAG-hygromycin
resistance cassette, and the SpCas9 gene was flanked by duplicated copies of
the core 300-bp HS4 insulator from the chicken β-globin gene to ensure proper
transgene expression (Fig. 1B).
For precise placement of SpCas9 at the porcine ROSA26 locus, we generated
a promoter trap vector consisting of a 2.2-kb 5′ homology arm corresponding
to a region of porcine ROSA26 intron 1; a 1.6-kb fragment composed of splice
acceptor, Kozak sequence, promoterless neomycin resistance gene, and a
triple-poly-A signal; a 5.3-kb SpCas9 expression cassette; and a 4.7-kb 3′ ho-
mology arm corresponding to a region of porcine ROSA26 introns 1 to 3. The
SpCas9 cassette contained a 0.8-kb CBh promoter (47), followed by an SV40
NLS, a 4.1-kb SpCas9 gene, a nucleoplasmin NLS, and a 0.2-kb BGHpA (Fig. 1A).
The gRNA constructs directed against EGFP and chicken B2Mwere generated
by cloning the respective gRNA oligonucleotides (EGFP: 5′-CCGGCAAGCTGCCCG-
TGCCC-3′; chicken B2M: 5′-GAACGTCCTCAACTGCTTCG-3′) with additional BbsI
overhangs into a BbsI-digested pBluescript II KS (+) vector carrying a 0.2-kb U6
promoter and a single-guide RNA (sgRNA) scaffold sequence. The gRNA con-
structs directed against porcine GGTA1 and B2M were generated by cloning the
respective gRNA oligonucleotides (GGTA1 exon 7: 5′-GTCGTGACCATAACCAGA-
3′; porcine B2M exon 1: 5′-TAGCGATGGCTCCCCTCG-3′), with additional BbsI
overhangs into a BbsI-digested vector carrying a 0.2-kb U6 promoter, an sgRNA
scaffold sequence, and, additionally, a 1.6-kb puromycin resistance cassette
composed of a 0.8-kb CBh promoter, a 0.6-kb puromycin resistance gene, and a
0.2-kb BGHpA. Oligonucleotides were synthesized by Eurofins Genomics. In
chickens, gRNAs were also delivered by the RCAS system. The sequences coding
for gRNAs and a human U6 promoter were introduced into the ClaI restriction
site of the RCASBP(A) vector as previously described (48, 49).
For AAV-mediated in vivo delivery of gRNAs directed against target sites
in porcine MYBPC3 exon 6 and exon 23, a construct was generated con-
sisting of 1) intact and Δtrs inverted terminal repeats (ITRs) of AAV2 (0.1 kb
each), 2) expression cassettes (0.4 kb each) for gRNAs directed against
MYBPC3 exon 6 (5′-GCTGTGAGGTATCCACCA-3′) and exon 23 (5′-GACTCC-
TGCACGGTGCAGT-3′) driven by human and murine U6 promoters, respec-
tively, and 3) a 1.2-kb mCherry cassette composed of a truncated CMV
promoter, an mCherry coding sequence, and a synthetic polyA.
Generation of SpCas9-Expressing Cells. Gene targeting in porcine cells was
performed in porcine kidney fibroblasts that were isolated and cultured by
standard methods (50). Cells were transfected with 4 μg to 6 μg of linearized
targeting vector DNA (ROSA26-SpCas9) using Lipofectamine 2000 transfec-
tion reagent (Thermo Fisher Scientific), selected with 1,400 μg/mL to
1,600 μg/mL G418 (Genaxxon Bioscience) for 7 d to 10 d, and targeted clones
identified by 5′- and 3′-junction PCR and DNA sequence analysis.
For the generation of transgenic chickens, EGFP-PGCs were derived from the
germinal crescent as previously described (51); 5 × 106 of EGFP-PGCs were
resuspended in a total volume of 100 μL of Nucleofector Solution V (Lonza)
premixed with 10 μg of Cas9 plasmid and the same amount of phiC31 integrase
Rieblinger et al. PNAS | 5 of 9
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(52). Electroporation was conducted by ECM 830 Square Wave Electroporation
System (BTX) using eight square wave pulses (350 V, 100 μs). After transfection,
cells were plated on 48-well plates and selected with 50 μg/mL hygromycin.
Animals. Permission for the generation of transgenic Cas9-expressing chickens
and pigs, and for the animal experiments, was issued by the government of
Upper Bavaria, Germany (ROB-55.2-2532.Vet_02-17-101 for chickens; ROB-
55.2-2532.Vet_02-18-33 and AZ 55.2-2532.Vet_02-18-79 for pigs). Experiments
were performed according to the German Welfare Act and European Union
Normative for Care and Use of Experimental Animals. All animals received
standard diet and water ad libitum.
Transgenic pigs were generated as previously described (53). Donor cells
were arrested at G0/G1 phase by serum deprivation. Oocytes, isolated from
prepubertal gilts, were maturated in vitro and enucleated, and single donor
cells were inserted into the perivitelline space. Cells were fused, and oocytes
activation was induced via electric pulse. Reconstructed embryos were then
transferred into the oviducts of hormonally synchronized recipient sows.
Transgenic chickens were generated as previously described (54). Briefly,
3,000 Cas9-PGCs were injected into the vasculature of 65-h-old embryos
(Lohmann selected White Leghorn line, Lohmann-Tierzucht GmbH), subse-
quently transferred into a turkey surrogate shell, and incubated until hatching
of chimeric roosters. Upon sexual maturity, sperm was collected for DNA iso-
lation and genotyping. After breeding with wild-type hens, fully Cas9 trans-
genic chickens were obtained.
Derivation and Functional Assays in SpCas9-Expressing Cells. PEFs, PADMSCs,
PAECs, and PKFswere isolated, according to standard protocols (50, 55, 56), from
an SpCas9-expressing pig and cultured in Dulbecco´s Modified Eagle Medium
(DMEM) (PEFs and PKFs) or Advanced DMEM (PADMSCs and PAECs) supple-
mented with 20% fetal bovine serum (FBS), 2 mM Ala-Gln, 1× MEM nones-
sential amino acid solution, and 1 mM sodium pyruvate (Corning) at 37 °C and
5% CO2. Cells were then transfected with 1 μg of gRNA constructs against
porcine B2M or GGTA1 using Lipofectamine 2000 transfection reagent, and,
24 h posttransfection, transiently transfected cells were selected using 1.5 μg/mL
puromycin (InvivoGen) for 2 d. The remaining cell pool was analyzed by flow
cytometry. PEFs were further transfected with 25 pmol of chemically modified
gRNAs directed against porcine B2M (G*U*A*GCGAUGGCUCCCCUCG) or por-
cine P16 (G*A*G*GCUAGCCAGUCGGCCGA) (Synthego) using Stemfect RNA
Transfection Kit (Stemgent) according to the manufacturer’s instruction.
To test SpCas9-expressing PGCs before injection into the embryo, 4 × 106
cells were electroporated with 10 μg of DNA of pBluescript II SK(+) DNA
vector containing a gRNA directed against EGFP using the Nucleofector V Kit
(Lonza). Subsequently, cells were analyzed for loss of EGFP expression by
flow cytometry.
Chicken embryonic fibroblasts (CEFs) were prepared from Cas9-positive
embryos as previously described (57) and cultured in Iscove’s medium supple-
mented with 5% FBS, 2% chicken serum, and 1% Penicillin/Streptomycin at
40 °C and 5% CO2. Transfection with RCAS-gRNAs was performed using ViaFect
Transfection Reagent (Promega) according to the manufacturer’s instructions,
with slight modifications. Briefly, 2.5 × 105 cells were seeded in six-well plates;
24 h later, transfected with 500 ng of DNA (transfection reagent to DNA ratio
of 6:1); and incubated for 20 min at room temperature.
Transfection with synthetic gRNAs was conducted using Xfect RNA Trans-
fection Reagent Protocol-At-A-Glance (Takara) following the manufacturer’s
instructions. Twenty-four hours after seeding 100,000 EGFP-Cas9 CEF cells in a
24-well plate, these were transfected with 25 pmol of synthetic EGFP-gRNA
premixed with Xfect RNA transfection polymer and incubated for 4 h, and the
transfection mixture was then replaced by 500 μL of cell culture medium. Cells
were analyzed at different time points for indels and loss of EGFP expression.
Splenic CD45+ cells were derived from a Cas9-expressing animal and iso-
lated as previously described (58). The spleen was removed aseptically and
homogenized by passing it through a cell strainer. Cells were isolated by Ficoll
density gradient separation and directly electroporated with 25 pmol of
chemically modified gRNAs directed against CXCR4 (CXCR4_1434: A*A*A*UUC-
AAUGAGUAUGCCAG) or B2M (β2m_1444: U*C*U*UGGUGCCCGCAGAGGCG)
(Synthego) using the human T Cell Nucleofector Kit (Lonza) according to
manufacturer’s instructions. Cells were resuspended in RPMI, 10% FBS, 1%
Penicillin/Streptomycin, and 1% Glutamax and seeded on a 12-well plate, and
medium was replaced after 6 h. Forty-eight hours postelectroporation, cells
were analyzed by flow cytometry.
In Ovo Functionality of SpCas9 in Chicken Bursal B Cells. Transduction of em-
bryonic B cells was carried out using the RCAS retroviral gene transfer system as
previously described (35, 59–61) (Fig. 3B). Briefly, DF-1 cells were transfected
with RCASBP(A)-β2m-gRNA or MOCK RCASBP(A)-EGFP-gRNA using ViaFect
Transfection Reagent (Promega) according to the manufacturer’s instructions.
The transfected cells were cultured for 10 d to ensure completed infection.
Then 1 × 106 cells in 100 μL of DMEMwere injected into the allantoic cavity of
ED3-old embryos using a sterile 1-mL syringe. At ED10, blood was taken from
the embryos, and genotyping was performed to identify SpCas9-positive em-
bryos. At ED18, heart tissue was collected for RCAS detection by PCR with
primers RCAS_B2M_F (5′-CGAAGCAGTTGAGGACGTTC-3′) and RCAS_B2M_R
(5′-CATATTTGCATATACGATACAAGGC-3′) resulting in a 245-bp amplicon. The
bursa was dissected from the embryo to obtain B cells isolated by density
gradient centrifugation. Cells were then stained for β2m and analyzed by flow
cytometry.
Functionality of SpCas9 in Porcine Colonic Organoids. Colonic organoids were
isolated as follows: Colonic mucosa was incubated in dissociation buffer
(phosphate-buffered saline [PBS], 30 mM EDTA, and 10 mM dithiothreitol) for
20 min at 4 °C; colonic crypts were then mechanically separated under a mi-
croscope and embedded in Matrigel (Corning). Organoids were cultivated in
growth medium as previously described (62), with minor changes (50%mouse
Wnt3a-conditioned medium, 50 ng/mL mouse Wnt3a recombinant protein
[Biolegend], 15% mouse R-spondin1-conditioned medium, 1.3% porcine
Noggin-conditioned medium, 2.5 μM CHIR99021 [Calbiochem/Merck], 100 μg/mL
primocin [Invitrogen]). Colonic organoids were electroporated with 2 μg of
gRNA construct as previously described (63) using the BTX ECM 830 with the
following instrument settings: 180 V, two pulses of 5-ms length, and 100-ms
pulse interval. After 24 h, cells were selected using 1 μg/mL puromycin (InvivoGen)
for 48 h, and cell pools were analyzed for the presence of indels.
AAV Preparation and G2-PAMAM Coating. Recombinant self-complementary
AAVs of pseudotype 2/9 were produced using the triple transfection method
described previously (64). Briefly, HEK 293T cells were transfected with a vector
encoding mCherry and U6-driven gRNAs targeting MYBPC3 exons 6 and 23
(pscAAV-hU6.gRNA-mU6.gRNA-trCMV.mCherry), a vector encoding AAV2 rep
and AAV9 cap sequences, and the helper plasmid pAdDeltaF6 (Puresyn) using PEI
Max (Polysciences). After 72 h, cells were harvested, and the virus was purified by
iodixanol gradient centrifugation. The virus was further purified by gravity flow
size-exclusion purification using Sephadex G100 SF resin (Sigma-Aldrich) in
Econo-Pac columns (Bio-Rad). The virus was concentrated in phosphate-buffered
saline using Amicon Ultra-15 centrifugal filter units (Merck, Germany) and stored
at 4 °C. Viral titers were quantified by qPCR using a probe binding the inverted
terminal repeat. For G2-PAMAM coating, 1 × 1014 virus genomes were mixed
with 18 μg of G2-PAMAM nanoparticles (Andrews ChemServices) in Opti-MEM I
(Thermo Fisher Scientific) by gentle pipetting and incubated for 30 min at room
temperature before further use.
AAV Infusion into Cas9-Expressing Pigs. Pigs (n = 2) were anesthetized, intu-
bated, and ventilated. Two 6F sheaths were inserted into the carotid artery and
the external jugular vein. For antegrade AAV9-gRNA infusion (1 × 1014 virus
genomes), the coronary target artery (LAD) was blocked by an over-the-wire
(OTW) balloon of 2.5 mm diameter, distal to the second diagonal branch.
Through the lumen of the OTWballoon, 10 mL of saline solution containing the
virus load was injected in fractions of 1 mL/min. During that period, the venous
outflow was blocked by a Swan Ganz catheter inserted deeply into the anterior
interventricular vein, accompanying the LAD. With this technique, the transi-
tion time of fluid was decelerated significantly to about 30 s. After injection of
10 mL, the balloons were deflated and removed. After a final demonstration of
open coronary vessels and normal heart function, the catheters and sheaths
were removed, and wounds were closed surgically. Anesthesia was stopped,
and animals were extubated in the operating room. The animals were killed
after 3 wk, and the hearts were excised, sampled in a systematic manner (65),
and snap frozen in liquid nitrogen-cooled 2-methylbutane for further
investigation.
Analysis of In Vivo Functionality of SpCas9 in Porcine Hearts. Snap-frozen heart
tissue was sectioned by cryotome and counterstained with DAPI and WGA-
Alexa488 conjugate (Thermo Fisher Scientific). MCherry signal, indicating suc-
cessful transduction, was visualized with the Thunder imaging system (Leica).
Genomic DNA from heart tissue was isolated by Proteinase K (Carl-Roth) diges-
tion and phenol-chloroform extraction. Deletion of the fragment between the
MYBPC3_Ex6 and MYBPC3_Ex23 gRNA target sites was screened by PCR using
Q5 polymerase (New England Biolabs) and flanking primers ∼0.6 kb distal to the
gRNA target sites (Table 1). Correctness of amplified bands was confirmed by
Sanger sequencing. Efficiency of editing was determined by qPCR using Viia7
Real-time PCR System (Applied Biosystems). Briefly, MYBPC3 wild-type exon 6
and the deletion variant (g41575_16906 del) were amplified by PCR using the
primers MYBPC3_Ex6_F (5′-GCCCCAAGTCTCCTCTAACA-3′) and MYBPC3_Ex6_R
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(5′-TCACCTATTCACCTGTGCCC-3′) for exon 6 and MYBPC3_Ex6_F and MYBPC3_
Del_R (5′-CAATGGGCATGAAGGGCTG-3′) for the deletion variant. Amplicons
were quantified photospectometrically, standard curves were generated by se-
rial dilution, and initial quantities of both amplicons in the tissue sample were
determined by qPCR using the primers above. The frequency of the deletion
variant was obtained by calculating the ratio of wild-type exon 6 to the deletion
variant.
In Vivo Functionality of SpCas9 in the Chicken Central Nervous System. Central
nervous tissue (neurons and glial cells) was transfected using in ovo electro-
poration (66–70). Briefly, Cas9xWT and Cas9xEGFP embryos at developmental
stages HH 10 to 13 (after ∼44 h of incubation) were transfected with a
pBlueScript II SK (+) vector containing a gRNA directed against B2M or EGFP.
Adhesive tape was attached to the eggshell to prevent cracks, and 2 mL of
albumin was extracted from the egg using a syringe. A window of about 1 cm2
to 2 cm2 was cut into the upper side to expose the blastodisc with the embryo
and illuminated with blue light to increase contrast. The plasmid solutions were
mixed 4:1 with Fast Green Dye resulting in 667 ng/μL pBlueScript II SK (+) vector
containing a gRNA against B2M and 1,255 ng/μL pBlueScript II SK (+) vector
containing a gRNA against EGFP. A small volume of plasmid solution filling only
the tip of a 100-μm glass micropipette was then injected into the mesencephalic
vesicle (second brain vesicle). Next, a gold electrode (positive) was positioned at
about 1 mm distance to the left of the embryo, and a tungsten microelectrode
(negative) was inserted into the second brain vesicle. For electroporation, three
rectangular pulses at 2 Hz with 15 V each and 25-ms duration were applied
(Grass S48 stimulator, Medical Instruments with Genetrodes 45-0115, Harvard
Apparatus Inc.). Electrodes were removed, and 1 mL to 2 mL of 4 °C chicken
ringer solution (150 mMNaCl, 5.4 mMKCl, 2.2 mM CaCl2, and 2.4 mM NaHCO3)
was dripped onto the embryo for liquid resupply and to reduce damage caused
by heating. The eggshells were sealed with adhesive tape, and the embryos
were incubated until ED12, when the embryonic brains were dissected for
genotyping, TIDE analysis, and histological preparation of midbrain slices of
EGFP-positive embryos. For histological analysis of EGFP-positive embryos, the
ED12 midbrains including the optic tectum (OT) were fixed in 4% parafor-
maldehyde for at least 24 h, transferred into 30% sucrose solution for 4 h for
cryoprotection, cryosectioned to 50 μm, and mounted with DAPI mounting
medium (0.1 mg DAPI in 100 mL n-propyl gallate). All images were taken with
an epifluorescence microscope (Olympus BX63 with XM10 digital camera,
Olympus) using the same exposure time and gain.
Indel Detection. Cell pools were analyzed for the presence of indels by PCR
spanning the gRNA target site using primers presented in Table 1. The
resulting amplicons were sequenced (Eurofins Genomics) and analyzed with
TIDE (http://shinyapps.datacurators.nl/tide/) (71). Amplicon sequencing over
the B2M target region was carried out by Genewiz.
Genotyping PCRs. The following primers were used to identify correct placement
of SpCas9 at the porcine ROSA26 locus: 5′-junction PCR used primers ROSA26_5′F
(5′-TATGGGCGGGATTCTTTTGC-3′) and Neo_5′R (5′-AGCCCCTGATGCTCTTCGTC-
3′) to amplify a 3.1-kb fragment; 3′-junction PCR used primers Cas9_3′F (5′-GCA-
GATCAGCGAGTTCTCCA-3′) and ROSA26_3′R (5′-CAGGTGGAAAGCTACCCTAGC-
C-3′) to amplify a 5.6-kb fragment. The wild-type ROSA26 allele was amplified
with primers ROSA26_5′F (sequence above) and ROSA26_I1R (5′-GTTTGCACA-
GGAAACCCAAG-3′), producing a 3.1-kb fragment. PCRs were carried out using
AccuStart Taq DNA polymerase HiFi (QuantaBio) and thermal cycling conditions:
94 °C for 1 min, followed by 40 cycles at 94 °C for 20 s, 60 °C for 30 s, 78 °C for
1 min per kb, and a final extension at 68 °C for 5 min.
The following primers were designed for the specific detection of SpCas9
in transgenic chickens Cas9-593-For (5′-GAGAGAATGAAGCGGATCGAAGAG-
3′) and Cas-440-Rev (5′–TTGCTGTAGAAGAAGTACTTGGCG-3′). PCRs were
carried out using FIREPol DNA Polymerase (Solis Biodyne) and thermal cy-
cling conditions: 95 °C for 5 min, followed by 40 cycles at 95 °C for 30 s, 58 °C
for 30 s, 72 °C for 1 min per kb, and a final extension at 72 °C for 5 min.
Determination of the Transgene Copy Number by Droplet Digital PCR. Droplet
digital PCR (ddPCR)was performed as described previously (30). The transgene copy
number was determined using a fluorescence-labeled probe for SpCas9 ([5′FAM-
GCACGCCATTCTGCGGCGGC-BHQ3′]; primers used: ddSpCas9_F [5′-AGTTCAT-
CAAGCCCATCCTG-3′] and ddSpCas9_R [5′-TCTTTTCCCGGTTGTCCTTC-3′]) or
hygromycin ([5′FAM-TCGTGCACGCGGATTTCGGCTCCAA-3′]; primers used:
ddHygro_F [5′-CATATGGCGCGATTGCTGATC-3′] and ddHygro_R [5′-GTCAAT-
GACCGCTGTTATGC-3′]). GAPDH ([5′HEX-TGTGATCAAGTCTGGTGCCC-BHQ3′];
primers used: ddGAPDH_F [5′-CTCAACGACCACTTCGTCAA-3′] and ddGAPDH_R
[5′-CCCTGTTGCTGTAGCCAAAT-3′]) or β-actin ([5′HEX-GTGGGTGGAGGAGGCT-
GAGC-BHQ3′]; primers used: ddBeta_actin_F: [5′-CAGGATGCAGAAGGAGATCA-
3′] and ddBeta_actin_R: [5′-TCCACCACTAAGACAAAGCA- 3′]) were used as ref-
erences. The target gene was quantified using the QX100 system (Bio-Rad
Laboratories).
Transgene Expression Analysis. RNA from porcine samples was isolated using
Sure Prep RNA/DNA/Protein Purification Kit (Fisher Scientific) for cells, or the
innuSPEED tissue RNA kit (Analytic Jena) for tissues, and complementary DNA
(cDNA) was synthesized using the FastGene Scriptase (Nippon Genetics).
SpCas9 mRNA was detected with primers pCas9_F1 (5′-GCAGATCAGCGAGTT-
CTCCA-3′) and pCas9_R1 (5′-GGGAGGGGCAAACAACAGAT-3′), resulting in a
415-bp amplicon. Porcine GAPDH mRNA was detected with primers GAPDHF
(5′-TTCCACGGCACAGTCAAGGC-3′) and GAPDHR (5′-GCAGGTCAGGTCCAC-
AAC-3′), resulting in a 576-bp amplicon. PCR was performed using GoTaq G2
DNA Polymerase (Promega) according to the manufacturer’s instructions.
RNA from chicken samples was isolated by Reliaprep RNA Tissue Miniprep
System according to manufacturer instructions (Promega), followed by cDNA
synthesis using GoScript Reverse transcription mix (Promega). SpCas9 mRNA was
detected with primers chCas9_F1 (5′-GAGAGAATGAAGCGGATCGAAGAG-3′) and
chCas9_R2 (5′-CAGTTCCTGGTCCACGTACATATC-3′), resulting in a 150-bp ampli-
con. β-actin mRNA was detected with primers Beta_actin_F (5′-TACCACAATGTA-
CCCTGGC-3′) and Beta_actin_R (5′-CTCGTCTTGTTTTATGCGC-3′), resulting in a
300-bp amplicon. PCR was performed using FIREPol DNA Polymerase (Solis Bio-
dyne) according to the manufacturer’s instructions.
Table 1. Primers used for indel detection
sgRNA target site Forward primer (5′−3′) Tm (°C) Reverse primer (5′−3′) Temperature (°C) PCR size
GGTA1 exon 7 GCCAGTCACCACAAGCCATG 63.5 TGGCCCTGTGACACCATTCT 63.5 362 bp
pB2M exon 1 CCACCCAGTCCAACCTTTGCC 65.5 CCAGAGTTAGCGCCCGGAGT 65.8 377 bp
MYBPC3 Δ6 to 23 CTTGAGAGGCTGTTGTTGCTGG 66.7 GCACACCCCATCTCTGATTCCT 67.2 1,225 bp
EGFP ATGGTGAGCAAGGGCGAGGAGCT 70.0 CGTCCTCGATGTTGTGGCGGATC 66.9 523 bp
chB2M CAAGGTGCAGGTGTACTCC 59.4 ACTTGTAGACCTGCGGCTC 61.1 269 bp
Table 2. Antibodies used for flow cytometry
Antibody Company/origin Concentration
Anti chicken β2m F21-21(75) Cell culture supernatant 1:5 dilution
Anti pig-B2M-Biotin clone B2M-02 Sigma-Aldrich (SAB4700015) 20 μg/mL
Streptavidin-PE BD (554061) 2.5 μg/mL
CD45-FITC Biozol (SBA-8270-02) 5 μg/mL
CXCR4 Bio-Rad (MCA6012GA) 0.2 μg/mL
H+L-APC Biozol (MBS-MBS4151013) 0.625 μg/mL
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Immunofluorescence. Cytoplasmic detection of Cas9 in the generated PGC
clones was done by FLAG-Tag staining. Briefly, a total number of 5 × 105 cells
were centrifuged, washed with PBS, and incubated with 100 μL of fixation
buffer (eBioscience) for 10 min. Cells were washed with 2% bovine serum al-
bumin (BSA) in PBS (FLUO-Buffer) followed by permeabilization with 0.1%
Triton X-100 in PBS for 10 min. Cells were incubated for 1 h with mouse anti-
FLAG M2 antibodies at a dilution of 1:500 in FLUO-Buffer. Subsequently, cells
were washed in PBS and incubated with an Alexa 568 secondary anti-mouse
IgG for 1 h in the dark. Cells were washed in PBS and resuspended in 20 μL of
mounting medium supplemented with DAPI, and immunofluorescence was
detected under a fluorescence microscope (ApoTome, Zeiss).
Flow Cytometry. Extracellular stainingwas carriedout to detect β2mand CXCR4.
Briefly, 3 × 105 to 1 × 106 cells were washed with 2% BSA in PBS (FLUO-Buffer).
To determine the living cell population, cells were incubated with Fixable Vi-
ability Dye eFluor 780 (eBioscience) at a dilution of 1:1,000. After washing with
FLUO-Buffer, primary antibodies (concentration shown in Table 2) were applied
for 20 min. Cells were washed in FLUO-Buffer to remove unbound antibodies
and incubated with conjugated secondary antibodies for 20 min. Subsequently,
cells were again washed and analyzed using an Attune flow cytometer (Thermo
Fisher Scientific). To detect CD45+ cells, a direct fluorescein isothiocyanate
(FITC)-labeled primary antibody was used, and the cells were washed with
FLUO-Buffer before analysis. Antibodies and concentrations used are shown in
Table 2.
For intracellular staining, cells were fixed and permeabilized with 0.1%
Triton X-100 in PBS for 10 min. The subsequent staining process was carried
out as described above. Detection of EGFP signal loss in different cells was
examined by quantifying the loss of EGFP signal. For all flow cytometry
analyses, an Attune flow cytometer (Thermo Fisher Scientific) was used. Data
were analyzed with FlowJo 10.4.1 software (FlowJo, LLC 2006-2017).
Statistical Analysis. Statistical analysis was carried out using SPSS24 statistics
(version 24.0.0.0) software (IBM). Normally distributed data (Shapiro−Wilk test
P > 0.05) were analyzed by student’s t test. The Mann−Whitney U Test was
applied for not normally distributed data. P values < 0.05 were considered as
significant. Graphs were constructed using GraphPad Prism (version 8.0.1 145)
(GraphPad Software).
Data Availability. All study data are included in the article and SI Appendix.
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